Govt Amends NDCT Rules to Cut Drug Approval Timelines

30 Jan 2026 CW Team

The Union Ministry of Health and Family Welfare has recently notified key amendments to the New Drugs and Clinical Trials (NDCT) Rules, 2019, aimed at reducing regulatory burden and improving Ease of Doing Business in the pharmaceutical sector. The changes focus on simplifying approval processes and significantly shortening timelines for drug development and clinical research.

Under the revised framework, the requirement for pharmaceutical companies to obtain a test licence from the Central Drugs Standard Control Organization (CDSCO) for non-commercial manufacture of small quantities of drugs for research or analysis has been replaced with a prior-intimation system. Companies may now proceed after submitting an online intimation, except for a limited category of high-risk drugs such as cytotoxic, narcotic and psychotropic substances. This move is expected to save at least 90 days in the drug development cycle.

For categories where test licences continue to apply, the statutory processing timeline has been reduced from 90 days to 45 days. With CDSCO handling nearly 30,000–35,000 such applications annually, the reform is expected to substantially ease compliance requirements for the industry.

In another major change, prior approval for certain low-risk Bioavailability and Bioequivalence (BA/BE) studies has been waived. These studies can now commence based on a simple online intimation, benefiting the generic pharmaceutical segment. CDSCO processes around 4,000–4,500 BA/BE applications each year.

Dedicated online modules on the National Single Window System and the SUGAM portal will support seamless implementation. Overall, the reforms are expected to accelerate research, optimise regulatory resources, and strengthen India’s position as a global hub for pharmaceutical R&D.

Resources

11 Feb 2026

KBL Expands Kaniyur Facility in Centenary Year

Kirloskar Brothers (KBL), a leading player in fluid management solutions, has inaugurated a new factory building at its Kaniyur Manufacturing Facility in Tamil Nadu. The expansion coincides with a milestone year marking 100 years since the company manufactured and installed India’s first centrifugal pump in 1926. The newly commissioned facility is aimed at enhancing productivity and operational efficiency, enabling the company to address rising domestic as well as international demand while upholding stringent quality benchmarks. Sustainability remains a central focus of the expansion. Ar..

Raimondi to Debut TRT 55US at CONEXPO

"Raimondi Group will present the TRT 55US rough terrain crane at CONEXPO 2026, marking the first product debut under its newly established Raimondi North America operations hub.Developed by Terex Rough Terrain, now part of the Raimondi portfolio, the 55-tonne model has been engineered specifically to meet North American operational, regulatory and environmental requirements.Designed for North American ApplicationsThe TRT 55US features a compact transport-friendly design, an additional jib configuration and a redesigned operator environment aimed at improving efficiency and precision. It offers..

CPCL Ranks No.1 in NHAI DPR Ratings

"Chaitanya Projects Consultancy (CPCL) has secured the top position in National Highways Authority of India’s first-ever provisional DPR consultants rating, scoring 80.75 out of 100 and outperforming 55 peer firms.CPCL ranked ahead of Pentacle Consultants (78), L&T Infrastructure Engineering (76), MSV International Technology (74) and Transys Consulting (72). The ranking, released in the fourth week of January 2026, marks NHAI’s first transparent evaluation framework aimed at enhancing DPR quality under Bharatmala and other national highway programmes.The move aligns with the accountab..